In this episode, I talk to Charles Brenner, a leading biochemist and outspoken critic of hype in the longevity field. We discuss why many aging studies in model organisms don’t always translate to humans, the limitations of current NAD-related therapies, and how publication bias harms scientific progress. He also shares what excites him most right now—his lab’s work on citrin deficiency and its potential for treating fatty liver disease and metabolic disorders.Visit the Brenner Lab to learn more about their exciting work: https://www.cityofhope.org/research/riggs-institute/diabetes-and-cancer-metabolism/charles-brenner-lab https://brennerlab.netGoogle Scholar: https://scholar.google.com/citations?hl=en&user=XgEjtucAAAAJ&X: https://x.com/CharlesMBrenner